
https://www.science.org/content/blog-post/where-cancer-immunotherapy-works-and-doesn-t
# Where Cancer Immunotherapy Works (and Doesn't) (Mar 2016)

## 1. SUMMARY  
The 2016 commentary highlighted the rapid rise of checkpoint‑blocking antibodies (PD‑1 inhibitor pembrolizumab and CTLA‑4 inhibitor ipilimumab) and argued that their efficacy depends on the nature of tumor neoantigens. Citing a new *Science* paper that profiled lung adenocarcinoma and melanoma, the author noted that patients whose tumors displayed **clonal** (shared across most cancer cells) neoantigens responded far better to checkpoint blockade than those with highly **sub‑clonal** (heterogeneous) neoantigens. The piece also pointed out that squamous‑cell carcinomas often harbor few neoantigens, making them “target‑poor” and potentially less amenable to immunotherapy. The author suggested that small‑molecule drug developers might need to focus on such immunotherapy‑resistant tumor types.

## 2. HISTORY  
**Checkpoint‑blockade approvals and uptake**  
- **Pembrolizumab** (Keytruda) received FDA approval for melanoma (2014) and for PD‑L1‑positive non‑small‑cell lung cancer (NSCLC) in 2015; by 2023 it held >20 tissue‑specific indications, including both adenocarcinoma and squamous NSCLC. Real‑world data show overall response rates (ORR) of 20‑30 % in NSCLC, with higher rates (≈45 %) in tumors with high PD‑L1 expression.  
- **Ipilimumab** (Yervoy) remained a cornerstone for melanoma; combination ipilimumab + nivolumab (another PD‑1 blocker) became standard for many advanced melanomas and renal cell cancers, improving median overall survival to >4 years in some cohorts.  

**Biomarker evolution**  
- The 2016 *Science* finding that **clonal neoantigen burden** predicts response spurred a wave of translational work. Subsequent studies (e.g., 2017–2020) confirmed that **tumor mutational burden (TMB)** and the proportion of clonal neoantigens are independent predictors of checkpoint efficacy across melanoma, NSCLC, and bladder cancer.  
- In 2020 the FDA granted a **tissue‑agnostic indication** for pembrolizumab based on **high TMB (≥10 mut/Mb)**, directly reflecting the neoantigen‑centric logic of the article.  

**Personalized neoantigen vaccines**  
- Early‑phase trials (e.g., 2017–2022) from Moderna, BioNTech, and academic groups demonstrated that patient‑specific neoantigen peptide or RNA vaccines can safely prime T‑cell responses and, when combined with PD‑1 blockade, modestly improve progression‑free survival in melanoma and glioblastoma. As of late 2024, no vaccine has yet achieved regulatory approval, but phase III data are expected in 2025–2026.  

**Squamous‑cell carcinoma experience**  
- Contrary to the article’s suggestion that squamous tumors are “target‑poor,” subsequent work showed that **head‑and‑neck squamous cell carcinoma (HNSCC)** and **lung squamous NSCLC** often have **high TMB** and respond to PD‑1 blockade, especially when PD‑L1 is expressed. Pembrolizumab received FDA approval for first‑line treatment of PD‑L1‑positive squamous NSCLC in 2018, with ORR ≈ 20 % and durable responses in a subset.  
- However, certain squamous cancers (e.g., cutaneous squamous cell carcinoma in immunocompetent patients) still show lower neoantigen clonality and variable checkpoint efficacy, confirming that heterogeneity matters.  

**Business and policy impact**  
- The checkpoint‑inhibitor market grew from ≈ $2 billion in 2015 to > $30 billion in 2024, driven by the broadening label base. Companies that invested early (Merck, Bristol‑Myers Squibb, Roche) saw sustained revenue growth, while many small‑molecule oncology firms pivoted toward **immuno‑oncology combinations** (e.g., kinase inhibitors plus PD‑1 blockers).  
- Health‑technology assessments (HTA) in the US, EU, and Canada increasingly require **biomarker‑driven reimbursement** (PD‑L1 IHC, TMB sequencing), reflecting the article’s emphasis on patient‑specific antigen profiling.  

## 3. PREDICTIONS  
- **Prediction:** *Clonal neoantigen burden predicts response to PD‑1/CTLA‑4 blockade.*  
  **Outcome:** Confirmed. Multiple independent cohorts (2017‑2023) demonstrated that higher clonal neoantigen load correlates with better ORR and survival, leading to TMB‑based approvals.  

- **Prediction:** *Squamous‑cell carcinomas will be poor candidates for immunotherapy because they lack neoantigens.*  
  **Outcome:** Partially wrong. While some squamous subtypes (e.g., certain esophageal SCC) show modest responses, many (lung, head‑and‑neck) have high TMB and respond to PD‑1 inhibitors. The “target‑poor” notion holds only for a subset.  

- **Prediction:** *Small‑molecule developers will need to shift focus to immunotherapy‑resistant tumor types.*  
  **Outcome:** Largely accurate. By 2024, many small‑molecule oncology pipelines emphasize **combination strategies** (e.g., KRAS G12C inhibitors with PD‑1 blockers) and target **tumors with low immunogenicity** (e.g., certain pediatric sarcomas).  

- **Prediction (implicit):** *Personalized neoantigen targeting will become routine.*  
  **Outcome:** Not yet. Personalized vaccines remain experimental; large‑scale adoption is still 5–10 years away.  

## 4. INTEREST  
Rating: **8/10**  
The article anticipated key concepts—clonal neoantigens, TMB as a biomarker, and heterogeneity‑driven response differences—that have shaped modern immuno‑oncology, making it highly relevant to both scientific understanding and commercial strategy.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20160304-where-cancer-immunotherapy-works-and-doesn-t.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_